Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Institute of BioMedical Research Corp.: MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead | 401 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specialising in alternative... ► Artikel lesen | |
01.03. | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Provides Corporate Update | 276 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation... ► Artikel lesen | |
23.02. | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development | 501 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
22.02. | Institute of BioMedical Research Corp.: MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward | 640 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative... ► Artikel lesen | |
09.02. | Institute of BioMedical Research Corp.: MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward | 376 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 9, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
02.01. | Institute of BioMedical Research Corp.: MRES: M2MMA Gears Up for a Landmark Year in 2024 | 796 | ACCESSWIRE | CAPE TOWN / ACCESSWIRE / January 2, 2024 / CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / January 2, 2024 / Institute of Biomedical Research Corp. (OTC PINK: MRES), a vanguard entity at the forefront of nutraceutical... ► Artikel lesen | |
15.11.23 | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park | 373 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES): A pioneering force in nutraceutical biotechnology, specializing in alternative plant-based... ► Artikel lesen | |
14.11.23 | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office | 348 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 14, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative... ► Artikel lesen | |
03.11.23 | Institute of BioMedical Research Corp.: African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair | 324 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative... ► Artikel lesen | |
12.10.23 | Institute of BioMedical Research Corp.: M2MMA Announces 2024 Fight Schedule and Appoints CEO | 917 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 12, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
02.10.23 | Institute of BioMedical Research Corp.: M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements | 469 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 2, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
21.09.23 | Institute of BioMedical Research Corp.: M2Bio Sciences Closes JDAX Acquisition | 512 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 21, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
15.09.23 | Institute of BioMedical Research Corp.: M2Bio Sciences Pharmacology & Clinical Application of CBD | 519 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
13.09.23 | Institute of BioMedical Research Corp.: M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update | 586 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 13, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
17.08.23 | Institute of BioMedical Research Corp.: M2bio Sciences Announces Launch of Exclusive MMA Organization | 386 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 17, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES) ("Institute of Biomedical Research" or the "Company"), a pioneering force in nutraceutical... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,635 | +0,75 % | QIAGEN N.V.: Bessere Zusammenarbeit im Gesundheitswesen: QIAGEN stellt QIAstat-Dx Analyzer 2.0 mit Fernzugriff auf Testergebnisse vor | QIAstat-Dx Analyzer 2.0 mit Software-Version 1.6 ermöglicht mobilen Zugriff auf Testergebnisse, optimiert diagnostische Prozesse und verbessert die Patientenversorgung // QIAstat-Dx Analyzer 2.0 bietet... ► Artikel lesen | |
EVOTEC | 14,470 | +0,66 % | Biotech Report: Biontech nach Zahlen gesucht; Evotec leichter | (shareribs.com) Frankfurt / New York 21.03.2024 - Biotechnologie-Aktien zeigen sich am Donnerstag überwiegend fest und folgen dem breiten Markt nach oben. Biontech können kräftig zulegen. Auch an der... ► Artikel lesen | |
MORPHOSYS | 67,20 | 0,00 % | Kaum Impulse für die MorphoSys-Aktie (66,34 €) | Der Kurs der der MorphoSys-Aktie kommt kaum von der Stelle. Der jüngste Kurs betrug 66,34 Euro. Die Wertschätzung der privaten und institutionellen Investoren für die Aktie von MorphoSys hat sich heute... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 61,22 | +3,44 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients | In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with... ► Artikel lesen | |
VIKING THERAPEUTICS | 76,62 | -0,57 % | Zweite Chance: Nach Gewinnmitnahmen bietet diese Aktie eine neue Gewinnchance | ||
RECURSION PHARMACEUTICALS | 9,990 | -2,44 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
BIONTECH | 86,10 | +0,19 % | BioNTech-Aktie: Was für ein Ding! | Bernd Wünsche (Gurupress.de) - BioNTech wandert weiter die Kursleiter hinunter. Die Mainzer verloren am Mittwoch gut -4 %. Das ist allerdings auch ein Ausfluss der Zahlen, die das Unternehmen nun präsentiert... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 4,160 | +11,53 % | Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment | ||
4D MOLECULAR THERAPEUTICS | 31,460 | -11,90 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic... ► Artikel lesen | |
NUVALENT | 75,10 | -2,85 % | Nuvalent, Inc.: Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 | CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven... ► Artikel lesen | |
ANNEXON | 7,085 | -11,22 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones | Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 50,34 | +1,33 % | Ascendis Pharma and MoonLake Immunotherapeutics dropped from Wedbush list | ||
SPRINGWORKS THERAPEUTICS | 49,840 | +0,54 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
IMMUNOVANT | 31,930 | -1,18 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
BEAM THERAPEUTICS | 33,060 | -2,54 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |